Elanco Animal Health Incorporated ELAN
Elanco Animal Health Incorporated (NYSE: ELAN) is an animal health company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Zenrelia | Pruritus and atopic dermatitis in dogs | small molecule | Approved |
| Credelio Quattro | Fleas, ticks, heartworms, roundworms, hookworms, tapeworms in dogs | small molecule | Approved |
| Befrena | Canine allergic and atopic dermatitis | antibody | Approved |
| Seresto | Parasiticide | small molecule | Approved |
| Advantage Family | Parasiticide | small molecule | Approved |
| AdTab | Parasiticide | small molecule | Approved |
| Rumensin | Farm animal / ruminants | small molecule | Approved |
Recent results and decisions
- Nov 6, 2026submitted Credelio Quattro received positive opinion from European Medicines Agency for expansion into the EU with expected launch in Q1 2027.
Credelio Quattro received positive opinion from European Medicines Agency for expansion into the EU; expect to launch in Q1 2027, ahead of the season
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.